EP1615635A1 - Pharmaceutical combination comprising eletriptan and sodium bicarbonate - Google Patents

Pharmaceutical combination comprising eletriptan and sodium bicarbonate

Info

Publication number
EP1615635A1
EP1615635A1 EP04724671A EP04724671A EP1615635A1 EP 1615635 A1 EP1615635 A1 EP 1615635A1 EP 04724671 A EP04724671 A EP 04724671A EP 04724671 A EP04724671 A EP 04724671A EP 1615635 A1 EP1615635 A1 EP 1615635A1
Authority
EP
European Patent Office
Prior art keywords
eletriptan
sodium bicarbonate
migraine
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04724671A
Other languages
German (de)
French (fr)
Inventor
Michael John Humphrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUMPHREY, MICHAEL JOHN
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of EP1615635A1 publication Critical patent/EP1615635A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a combination comprising eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, the use of such a combination for the treatment or prevention of a disease for which a 5- HTi agonist is indicated and formulations and products comprising such a combination.
  • Eletriptan, 3- ⁇ [1 -methylpyrrolidin-2(R)-yl]methyl ⁇ -5-(2-phenylsulfonylethyl)-1 H- indole, and a process for its manufacture, are disclosed in United States Patent number 5,607,951.
  • Eletriptan is a potent 5-HTi agonist and may be used in the treatment of hypertension, depression, anxiety, eating disorders, emesis, obesity, drug abuse, cluster headache, migraine (including menstrual migraine and recurrent migraine), pain, chronic paroxysmal hemicrania or headache associated with vascular disorders (see US-B-5,607,951 , WO-A-96/06842 and WO-A-00/32589).
  • Eletriptan is useful in the treatment of migraine in children, in the treatment of mild migraine, menstrual migraine and early migraine and in the treatment of post-traumatic head and neck injury, mixed headaches and tension headaches.
  • eletriptan is also useful in the prevention of migraine recurrence.
  • compositions suitable for the oral administration of eletriptan, or a pharmaceutically acceptable salt thereof for example tablets or capsules, prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, fillers, lubricants, disintegrants or wetting agents, are known. Such compositions dissolve in the gastrointestinal tract and the released drug is absorbed into the blood stream after a certain time lag.
  • T max the time period that elapses between administering a standard tablet and observing maximal plasma concentrations of the drug in the bloodstream
  • a migraine attack can further increase T ma ⁇ , delaying drug absorption, by causing gastric stasis.
  • T ma was significantly slowed in patients with migraine (T max 2.8 ⁇ 2.1 h) when compared with migraine-free patients (T max 1.3 ⁇ 1.3h).
  • the present invention therefore provides a combination of eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate.
  • the invention further provides a combination of eletriptan, or a pharmaceutically acceptable salt thereof and sodium bicarbonate, for use as a medicament.
  • the invention further provides a combination of eletriptan, or a pharmaceutically acceptable salt thereof and sodium bicarbonate, for use in the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly for use in the treatment of migraine or in the prevention of migraine recurrence.
  • the invention further provides the use of (a) eletriptan, or a pharmaceutically acceptable salt thereof, or (b) sodium bicarbonate for the manufacture of a medicament for the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly for the treatment of migraine or for the prevention of migraine recurrence, wherein (a) and (b) are to be taken separately, sequentially or simultaneously by the oral route.
  • the invention further provides a method of treating or preventing a disease for which a 5-HTi agonist is indicated, particularly a method of treating migraine or preventing migraine recurrence, in a mammal, including a human being, including simultaneous, separate or sequential administration by the oral route of (a) an effective amount of eletriptan, or a pharmaceutically acceptable salt thereof and (b) an effective amount of sodium bicarbonate.
  • the invention further provides a pharmaceutical composition, suitable for oral administration, including eletriptan, or a pharmaceutically acceptable salt thereof, sodium bicarbonate and a pharmaceutically acceptable excipient, diluent or carrier.
  • the invention further provides a product containing (a) eletriptan, or a pharmaceutically acceptable salt thereof and (b) sodium bicarbonate as a combined preparation for simultaneous, separate or sequential use, via oral administration, in the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly in the treatment of migraine or in the prevention of migraine recurrence.
  • Pharmaceutically acceptable salts of eletriptan include the acid addition and base salts thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts
  • acids which form non-toxic salts
  • examples include the acetate, aspartate, benzoate, besylate bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate esylate, formate, fumarate, gluceptate, gluconate, glucuronate hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate saccharate, stearate, succinate, tartrate, tosylate
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Preferred salts of eletriptan in the context of the present invention are the hydrobromide and hemisulphate salts (see WO-A-96/06842 and WO-A- 01/23377), especially the hydrobromide salt.
  • a pharmaceutically acceptable salt of eletriptan may be readily prepared by mixing together eletriptan and the desired acid or base, as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • Pharmaceutically acceptable solvates of eletriptan, including hydrates and solvates wherein the solvent of crystallization may be isotopically substituted e.g. D 2 O, de-acetone, d 6 -DMSO
  • clathrates drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts.
  • Any polymorph of eletriptan, or a pharmaceutically acceptable salt thereof, may be used in the invention. Particularly preferred is the ⁇ -polymorphic form of eletriptan hydrobromide described in WO-A-96/06842 and the polymorphic form of eletriptan hemisulphate defined by the claims of WO-A-01/23377, particularly the former.
  • prodrugs of eletriptan and its pharmaceutically acceptable salts.
  • certain derivatives of eletriptan and its salts which have little or no pharmacological activity themselves can, upon administration into or onto the body, be converted, for example by metabolism or hydrolytic cleavage, to eletriptan itself.
  • Such derivatives are referred to as "prodrugs”.
  • Further information on the use of prodrugs may be found in 'Pro- drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in eletriptan with certain moieties known to those skilled in the art as “pro-moieties” as described, for example, in “Design of Prodrugs” by H Bundgaard (Elsevier, 1985).
  • prodrugs of particular importance are derivatives of the indole NH group, for example by replacement of the hydrogen atom with (d- C ⁇ o)alkanoyl.
  • the present invention also includes all pharmaceutically acceptable isotopic variations of eletriptan and its pharmaceutically acceptable salts.
  • An isotopic variation is defined as one in which at least one atom is replaced by an atom having the same atomic number, but an atomic mass different from the atomic mass usually found in nature.
  • isotopes include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 13 C and 14 C, nitrogen, such as 15 N, oxygen, such as 17 O and 18 O, phosphorus, such as 32 P, sulphur, such as 35 S, fluorine, such as 18 F, and chlorine, such as 36 CI.
  • substitution with isotopes such as deuterium, i.e. H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Radioactive isotopes for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • Isotopic variants of eletriptan and its salts can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the art for the preparation of eletriptan using appropriate isotopic variants of suitable reagents.
  • Eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate may be freeze-dried, spray-dried, or evaporatively dried to provide a solid plug, powder, or film of crystalline or amorphous material. Microwave or radio frequency drying may be used for this purpose.
  • the compounds of the invention may be administered alone but will generally be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
  • excipient is used herein to describe any ingredient other than the compound of the invention.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, films (including muco-adhesive), ovules, sprays and liquid formulations.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast- disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, (6), 981-986 by Liang and Chen (2001).
  • Tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
  • the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form. It is preferred that tablets made according to the present invention should comprise microcrystalline cellulose as a disintegrant.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. It is preferred that tablets made according to the present invention should comprise microcrystalline cellulose as a binder.
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents such as sodium lauryl sulfate and polysorbate 80
  • glidants such as silicon dioxide and talc.
  • surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally comprise from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet. It is preferred that tablets made according to the present invention should comprise magnesium stearate as a lubricant.
  • ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
  • the compounds of the invention may be combined with soluble macromolecular entities such as cyclodextrin or polyethylene glycol-containing polymers to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability. Both inclusion and non-inclusion complexes may be used.
  • a cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.
  • the total daily dose of eletriptan is typically in the range from 0.1 mg to 4 mg/kg, in single or divided doses. A single first dose of 40mg is currently recommended.
  • the physician in any event, will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
  • tablets or capsules according to the invention will typically contain from 5 to 240 mg, preferably from 5 to 100mg of eletriptan, for administration singly or two or more at a time, as appropriate.
  • tablets comprising (a) 40mg of eletriptan in the form of its hydrobromide salt for administration singly or (b) 20mg of eletriptan in the form of its hydrobromide salt for administration two at a time are provided.
  • Enough sodium bicarbonate should preferably be administered to obtain a duodenal concentration approximately isotonic with serum (150miV1). So, for instance, if the combination of the invention is to be taken with half a tumbler of water (100ml) in fasted volunteers, 1260mg of sodium bicarbonate would be required to provide such an isotonic solution. Such a dose of sodium bicarbonate is too large to be incorporated conveniently into a single tablet. It is thus preferred that, where the combination is to be administered simultaneously in the form of a tablet, tablets comprising about 630mg sodium bicarbonate for administration two at a time are provided. Alternatively, if the combination of the invention is to be taken with 50ml of water, a single tablet containing about 630mg of sodium bicarbonate is preferred.
  • a combination or formulation according to the invention comprises greater than 50% (preferably greater than 55%) by weight of sodium bicarbonate.
  • the eletriptan, or salt thereof, and bicarbonate are administered simultaneously, preferably in the form of a tablet containing both compounds.
  • such a tablet contains from 20 to 40mg of eletriptan (in the form of its hydrobromide salt) in combination with from 300 to 1300mg, most preferably about 630mg, of sodium bicarbonate.
  • such a tablet contains from 20 to 40mg, most preferably 20 or 40mg, of eletriptan (in the form of its hydrobromide salt) in combination with about 630mg of sodium bicarbonate.
  • the present combination of eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate may also be administered in combination with one or more further active substances.
  • further active substances include:
  • a further antimigraine drug particularly a further triptan such as sumatriptan, naratriptan, rizatriptan, almotriptan, avitriptan, frovatriptan or zolmitriptan;
  • a prokinetic agent such as those mentioned in WO-A-02/070070, e.g. metaclopramide;
  • an alkylxanthine compound such as caffeine, theophylline or theobromine, particularly caffeine.
  • NSAID non-steroidal anti-inflammatory drug
  • COX-2 inhibitor e.g. celecoxib or valdecoxib.
  • the combination of eletriptan, or a salt thereof, and sodium bicarbonate may also further comprise a pharmaceutically acceptable acidic agent such that on exposure to an aqueous medium the combination will dissolve in an effervescent manner.
  • suitable pharmaceutically acceptable acidic agents include adipic acid, ascorbic acid, citric acid, fumaric acid, glycolic acid, lactic acid, maleic acid, alic acid, succinic acid and tartaric acid. Citric acid and adipic acid are preferred.
  • the combination of the present invention may be conveniently presented in tablet form along with a suitable quantity of water with which the tablet or tablets can be taken.
  • the invention therefore further provides a product comprising (a) eletriptan, or a pharmaceutically acceptable salt thereof, (b) sodium bicarbonate, (c) water and (d) suitable packaging.
  • such a product contains either (a) two tablets, each containing 20mg of eletriptan (in the form of its hydrobromide salt) and about 630mg of sodium bicarbonate, and about 100ml of water or (b) one tablet containing 40mg of eletriptan (in the form of its hydrobromide salt) and about 630mg of sodium bicarbonate, and about 50ml of water.
  • any 5-HTi agonist can in principle be combined with sodium bicarbonate in order to obtain an increased rate of gastrointestinal absorption when delivered by the oral route.
  • Such 5-HTi agonists include almotriptan, alnatriptan, avitriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan.
  • the invention therefore further provides a non-effervescent composition adapted for oral administration and gastrointestinal drug absorption comprising a 5-HTi agonist and sodium bicarbonate.
  • non-effervescent means that when the composition is dissolved in water at pH 7, no effervescence is observed.
  • composition comprising a 5-HTi agonist and sodium bicarbonate.
  • the composition comprises greater than 50% (preferably greater than 55%) by weight of sodium bicarbonate.
  • Tablets comprising eletriptan hydrobromide and sodium bicarbonate
  • a mixture of eletriptan hydrobromide (24.24mg, equivalent to 20mg of eletriptan free base), sodium bicarbonate (USP, 630mg) and microcrystalline cellulose (Avicel PH 102, Ph. Eur., 137.76mg) were blended for 10 minutes, passed through a 500 ⁇ M screen and re-blended for a further 10 minutes. Screened intragranular magnesium stearate (Ph. Eur., 8mg) was added and the mixture was lubricated for 5 minutes.
  • the blend so obtained was found to have a particle size range from approximately 200 ⁇ m to 1 mm and to have excellent flow properties.
  • the blend was made into a tablet by direct compression. The tablets so produced had excellent weight uniformity and friability.
  • Examples 2 to 4 in Table 1 describe further tablets made according to the method of Example 1.
  • the lactose and croscarmellose sodium were added to the initial mixture before blending.
  • the objective of this study was to measure plasma concentrations of eletriptan in four beagle dogs following administration of tablets comprising eletriptan with and without sodium bicarbonate as single oral doses and thus to determine the effect of sodium bicarbonate on the rate of absorption and exposure of eletriptan.
  • beagles were used in the study, two male and two female. Each beagle received one of study formulations and blood samples were then taken during a subsequent 24 hour period (every 5 minutes for the first 45 minutes) to monitor plasma levels of eletriptan. The beagles subsequently received the alternative formulation and blood samples were taken in an identical fashion. At least one week was allowed to elapse between treatments.

Abstract

The present invention provides a combination of (a) eletriptan, or a pharmaceutically acceptable salt thereof, and (b) sodium bicarbonate. The combination provides a rapid absorption of eletriptan when taken orally. The combination is useful for the treatment or prevention of a disease for which a 5-HT1, agonist is indicated, particularly for the treatment of migraine or for the prevention of migraine recurrence.

Description

PHARMACEUTICAL COMBINATION COMPRISING ELETRIPTAN AND SODIUM BICARNONATE
The present invention relates to a combination comprising eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, the use of such a combination for the treatment or prevention of a disease for which a 5- HTi agonist is indicated and formulations and products comprising such a combination.
Eletriptan, 3-{[1 -methylpyrrolidin-2(R)-yl]methyl}-5-(2-phenylsulfonylethyl)-1 H- indole, and a process for its manufacture, are disclosed in United States Patent number 5,607,951.
Eletriptan is a potent 5-HTi agonist and may be used in the treatment of hypertension, depression, anxiety, eating disorders, emesis, obesity, drug abuse, cluster headache, migraine (including menstrual migraine and recurrent migraine), pain, chronic paroxysmal hemicrania or headache associated with vascular disorders (see US-B-5,607,951 , WO-A-96/06842 and WO-A-00/32589).
Eletriptan is useful in the treatment of migraine in children, in the treatment of mild migraine, menstrual migraine and early migraine and in the treatment of post-traumatic head and neck injury, mixed headaches and tension headaches.
As disclosed in WO-A-00/06161 , eletriptan is also useful in the prevention of migraine recurrence.
Pharmaceutical compositions suitable for the oral administration of eletriptan, or a pharmaceutically acceptable salt thereof, for example tablets or capsules, prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, fillers, lubricants, disintegrants or wetting agents, are known. Such compositions dissolve in the gastrointestinal tract and the released drug is absorbed into the blood stream after a certain time lag. For instance, when eletriptan is administered in the form of the α-polymorphic hydrobromide salt disclosed in WO-A-96/06842, the time period that elapses between administering a standard tablet and observing maximal plasma concentrations of the drug in the bloodstream (Tmax) ranges from about 1 hour in fasted subjects to up to about 4 hours in fed subjects.
Problematically, a migraine attack can further increase Tmaχ, delaying drug absorption, by causing gastric stasis. For instance, in one study in which 30mg eletriptan was administered to 34 fasted subjects, with and without migraine, Tma was significantly slowed in patients with migraine (Tmax 2.8 ± 2.1 h) when compared with migraine-free patients (Tmax 1.3 ± 1.3h).
Clearly, there exists a need to minimise the time lag between the administration of eletriptan, or a pharmaceutically acceptable salt thereof, orally and the relief of symptoms brought about by the delivery of the drug via the bloodstream to important tissues.
It has now been surprisingly found that when eletriptan, or a pharmaceutically acceptable salt thereof, is administered in combination with sodium bicarbonate, via the oral route, the time lag between oral administration and maximal plasma levels of drug is dramatically reduced, in some cases to as little as 30 minutes. The advantage to the patient arising from the correspondingly swift amelioration of symptoms is self-evident.
The present invention therefore provides a combination of eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate.
The invention further provides a combination of eletriptan, or a pharmaceutically acceptable salt thereof and sodium bicarbonate, for use as a medicament. The invention further provides a combination of eletriptan, or a pharmaceutically acceptable salt thereof and sodium bicarbonate, for use in the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly for use in the treatment of migraine or in the prevention of migraine recurrence.
The invention further provides the use of (a) eletriptan, or a pharmaceutically acceptable salt thereof, or (b) sodium bicarbonate for the manufacture of a medicament for the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly for the treatment of migraine or for the prevention of migraine recurrence, wherein (a) and (b) are to be taken separately, sequentially or simultaneously by the oral route.
The invention further provides a method of treating or preventing a disease for which a 5-HTi agonist is indicated, particularly a method of treating migraine or preventing migraine recurrence, in a mammal, including a human being, including simultaneous, separate or sequential administration by the oral route of (a) an effective amount of eletriptan, or a pharmaceutically acceptable salt thereof and (b) an effective amount of sodium bicarbonate.
The invention further provides a pharmaceutical composition, suitable for oral administration, including eletriptan, or a pharmaceutically acceptable salt thereof, sodium bicarbonate and a pharmaceutically acceptable excipient, diluent or carrier.
The invention further provides a product containing (a) eletriptan, or a pharmaceutically acceptable salt thereof and (b) sodium bicarbonate as a combined preparation for simultaneous, separate or sequential use, via oral administration, in the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly in the treatment of migraine or in the prevention of migraine recurrence. Pharmaceutically acceptable salts of eletriptan include the acid addition and base salts thereof.
Suitable acid addition salts are formed from acids which form non-toxic salts Examples include the acetate, aspartate, benzoate, besylate bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate esylate, formate, fumarate, gluceptate, gluconate, glucuronate hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.
Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Preferred salts of eletriptan in the context of the present invention are the hydrobromide and hemisulphate salts (see WO-A-96/06842 and WO-A- 01/23377), especially the hydrobromide salt.
A pharmaceutically acceptable salt of eletriptan may be readily prepared by mixing together eletriptan and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. Pharmaceutically acceptable solvates of eletriptan, including hydrates and solvates wherein the solvent of crystallization may be isotopically substituted (e.g. D2O, de-acetone, d6-DMSO), are also within the scope of the invention.
Also within the scope of the invention are clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. For a review of such complexes, see J. Pharm. Sci., 64 (8), 1269-1288 by Haleblian (August 1975).
Any polymorph of eletriptan, or a pharmaceutically acceptable salt thereof, may be used in the invention. Particularly preferred is the α-polymorphic form of eletriptan hydrobromide described in WO-A-96/06842 and the polymorphic form of eletriptan hemisulphate defined by the claims of WO-A-01/23377, particularly the former.
Also within the scope of the invention are so-called "prodrugs" of eletriptan and its pharmaceutically acceptable salts. Thus certain derivatives of eletriptan and its salts, which have little or no pharmacological activity themselves can, upon administration into or onto the body, be converted, for example by metabolism or hydrolytic cleavage, to eletriptan itself. Such derivatives are referred to as "prodrugs". Further information on the use of prodrugs may be found in 'Pro- drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association).
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in eletriptan with certain moieties known to those skilled in the art as "pro-moieties" as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985). In the case of eletriptan, prodrugs of particular importance are derivatives of the indole NH group, for example by replacement of the hydrogen atom with (d- Cιo)alkanoyl.
The present invention also includes all pharmaceutically acceptable isotopic variations of eletriptan and its pharmaceutically acceptable salts. An isotopic variation is defined as one in which at least one atom is replaced by an atom having the same atomic number, but an atomic mass different from the atomic mass usually found in nature. Examples of possible isotopes include isotopes of hydrogen, such as 2H and 3H, carbon, such as 13C and 14C, nitrogen, such as 15N, oxygen, such as 17O and 18O, phosphorus, such as 32P, sulphur, such as 35S, fluorine, such as 18F, and chlorine, such as 36CI.
Substitution with isotopes such as deuterium, i.e. H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Certain isotopic variations for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
Isotopic variants of eletriptan and its salts can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the art for the preparation of eletriptan using appropriate isotopic variants of suitable reagents.
Eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate (henceforth, 'compounds of the invention') may be freeze-dried, spray-dried, or evaporatively dried to provide a solid plug, powder, or film of crystalline or amorphous material. Microwave or radio frequency drying may be used for this purpose.
The compounds of the invention may be administered alone but will generally be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound of the invention.
The compounds of the invention are administered orally. Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, films (including muco-adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast- disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, (6), 981-986 by Liang and Chen (2001).
Tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form. It is preferred that tablets made according to the present invention should comprise microcrystalline cellulose as a disintegrant.
Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. It is preferred that tablets made according to the present invention should comprise microcrystalline cellulose as a binder.
Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet. It is preferred that tablets made according to the present invention should comprise magnesium stearate as a lubricant.
Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant. Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X).
The compounds of the invention may be combined with soluble macromolecular entities such as cyclodextrin or polyethylene glycol-containing polymers to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, a cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.
For administration to human patients, the total daily dose of eletriptan is typically in the range from 0.1 mg to 4 mg/kg, in single or divided doses. A single first dose of 40mg is currently recommended. The physician, in any event, will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
Thus, tablets or capsules according to the invention will typically contain from 5 to 240 mg, preferably from 5 to 100mg of eletriptan, for administration singly or two or more at a time, as appropriate. In especially preferred embodiments of the present invention, tablets comprising (a) 40mg of eletriptan in the form of its hydrobromide salt for administration singly or (b) 20mg of eletriptan in the form of its hydrobromide salt for administration two at a time are provided.
Enough sodium bicarbonate should preferably be administered to obtain a duodenal concentration approximately isotonic with serum (150miV1). So, for instance, if the combination of the invention is to be taken with half a tumbler of water (100ml) in fasted volunteers, 1260mg of sodium bicarbonate would be required to provide such an isotonic solution. Such a dose of sodium bicarbonate is too large to be incorporated conveniently into a single tablet. It is thus preferred that, where the combination is to be administered simultaneously in the form of a tablet, tablets comprising about 630mg sodium bicarbonate for administration two at a time are provided. Alternatively, if the combination of the invention is to be taken with 50ml of water, a single tablet containing about 630mg of sodium bicarbonate is preferred.
In one embodiment, a combination or formulation according to the invention (especially a tablet) comprises greater than 50% (preferably greater than 55%) by weight of sodium bicarbonate.
It is preferred that the eletriptan, or salt thereof, and bicarbonate are administered simultaneously, preferably in the form of a tablet containing both compounds.
Preferably, such a tablet contains from 20 to 40mg of eletriptan (in the form of its hydrobromide salt) in combination with from 300 to 1300mg, most preferably about 630mg, of sodium bicarbonate.
Preferably, such a tablet contains from 20 to 40mg, most preferably 20 or 40mg, of eletriptan (in the form of its hydrobromide salt) in combination with about 630mg of sodium bicarbonate. The present combination of eletriptan, or a pharmaceutically acceptable salt thereof, and sodium bicarbonate may also be administered in combination with one or more further active substances. Examples of such further active substances include:
(a) a further antimigraine drug, particularly a further triptan such as sumatriptan, naratriptan, rizatriptan, almotriptan, avitriptan, frovatriptan or zolmitriptan;
(b) a prokinetic agent such as those mentioned in WO-A-02/070070, e.g. metaclopramide;
(c) an alkylxanthine compound such as caffeine, theophylline or theobromine, particularly caffeine; and
(d) a non-steroidal anti-inflammatory drug (NSAID) such as a COX-2 inhibitor, e.g. celecoxib or valdecoxib.
In a further embodiment of the invention, the combination of eletriptan, or a salt thereof, and sodium bicarbonate, may also further comprise a pharmaceutically acceptable acidic agent such that on exposure to an aqueous medium the combination will dissolve in an effervescent manner. Examples of suitable pharmaceutically acceptable acidic agents include adipic acid, ascorbic acid, citric acid, fumaric acid, glycolic acid, lactic acid, maleic acid, alic acid, succinic acid and tartaric acid. Citric acid and adipic acid are preferred.
It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.
The combination of the present invention may be conveniently presented in tablet form along with a suitable quantity of water with which the tablet or tablets can be taken. The invention therefore further provides a product comprising (a) eletriptan, or a pharmaceutically acceptable salt thereof, (b) sodium bicarbonate, (c) water and (d) suitable packaging.
Preferably, such a product contains either (a) two tablets, each containing 20mg of eletriptan (in the form of its hydrobromide salt) and about 630mg of sodium bicarbonate, and about 100ml of water or (b) one tablet containing 40mg of eletriptan (in the form of its hydrobromide salt) and about 630mg of sodium bicarbonate, and about 50ml of water.
Whilst the invention has been described above with reference solely to eletriptan, or a pharmaceutically acceptable salt thereof, it has been shown that any 5-HTi agonist can in principle be combined with sodium bicarbonate in order to obtain an increased rate of gastrointestinal absorption when delivered by the oral route. Such 5-HTi agonists include almotriptan, alnatriptan, avitriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan.
The invention therefore further provides a non-effervescent composition adapted for oral administration and gastrointestinal drug absorption comprising a 5-HTi agonist and sodium bicarbonate.
In this context, non-effervescent means that when the composition is dissolved in water at pH 7, no effervescence is observed.
All preferred features relating to a combination of eletriptan and sodium bicarbonate, as described above, apply equally to the non-effervescent composition comprising a 5-HTi agonist and sodium bicarbonate. In particular, in one embodiment the composition comprises greater than 50% (preferably greater than 55%) by weight of sodium bicarbonate.
The following Examples illustrate the invention. 13
Examples 1-4
Tablets comprising eletriptan hydrobromide and sodium bicarbonate
A mixture of eletriptan hydrobromide (24.24mg, equivalent to 20mg of eletriptan free base), sodium bicarbonate (USP, 630mg) and microcrystalline cellulose (Avicel PH 102, Ph. Eur., 137.76mg) were blended for 10 minutes, passed through a 500 μM screen and re-blended for a further 10 minutes. Screened intragranular magnesium stearate (Ph. Eur., 8mg) was added and the mixture was lubricated for 5 minutes. The blend so obtained was found to have a particle size range from approximately 200μm to 1 mm and to have excellent flow properties. The blend was made into a tablet by direct compression. The tablets so produced had excellent weight uniformity and friability.
Surprisingly, it was found that eletriptan, at a tablet composition of 2.5% w/w, was able to confer extra strength to the tablets, as demonstrated by an increase of 0.7kp in tablet hardness relative to tablets made from a placebo blend.
Examples 2 to 4 in Table 1 describe further tablets made according to the method of Example 1. In the case of Examples 3 and 4, the lactose and croscarmellose sodium were added to the initial mixture before blending.
Table 1
Example 5
Pharmacokinetic evaluation of an eletriptan hvdrobromide/sodium bicarbonate tablet relative to a standard eletriptan hydrobromide tablet
The objective of this study was to measure plasma concentrations of eletriptan in four beagle dogs following administration of tablets comprising eletriptan with and without sodium bicarbonate as single oral doses and thus to determine the effect of sodium bicarbonate on the rate of absorption and exposure of eletriptan.
The following two formulations were compared:
(a) a commercially available 20mg tablet comprising eletriptan hydrobromide taken with 50ml water; and
(b) the tablet of Example 1 taken with 50ml water.
Four beagles were used in the study, two male and two female. Each beagle received one of study formulations and blood samples were then taken during a subsequent 24 hour period (every 5 minutes for the first 45 minutes) to monitor plasma levels of eletriptan. The beagles subsequently received the alternative formulation and blood samples were taken in an identical fashion. At least one week was allowed to elapse between treatments.
The results of the study are listed in Table 2. Mean values for the key pharmacokinetic parameters Tmax (time to maximum plasma concentration), Cmax (highest plasma concentration) and AUC (total exposure to drug - area under the curve from zero to infinity) are given as an average of the values for each dog. In the case of formulation (b), one dog vomited 15 minutes after treatment, leading to anomalous results which were not included in the calculations. Standard deviations from the mean values are also listed. Table 2
The results show that administration of a tablet comprising 20mg eletriptan and 630mg sodium bicarbonate with 50ml water results in a more rapid absorption of drug than administration of a commercial 20mg eletriptan tablet with 50ml water, as shown by a reduction in Tmax from a mean of 2.8 hours (± 2.2) to a mean of 1.2 hours (±0.3), i.e. an average reduction in Tmax of 57%. There is a corresponding increase in Cmax from a mean of 22.6ng/ml to a mean of 31.8ng/ml. Overall exposure, as measured by AUC is similar. Furthermore, inter-animal variability is greatly reduced following administration of formulation (b) comprising sodium bicarbonate as compared to administration of standard formulation (a).

Claims

Claims
1. A combination of (a) eletriptan, or a pharmaceutically acceptable salt thereof, and (b) sodium bicarbonate.
2. A combination as claimed in claim 1 wherein (a) is eletriptan hydrobromide or eletriptan hemisulphate.
3. A combination as claimed in claim 1 or claim 2, for use as a medicament.
4. A combination as claimed in claim 1 or claim 2 for use in the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly for use in the treatment of migraine or in the prevention of migraine recurrence.
5. The use of (a) eletriptan, or a pharmaceutically acceptable salt thereof, or (b) sodium bicarbonate for the manufacture of a medicament for the treatment or prevention of a disease for which a δ-H^ agonist is indicated, particularly for the treatment of migraine or for the prevention of migraine recurrence, wherein (a) and (b) are to be taken separately, sequentially or simultaneously by the oral route.
6. A method of treating or preventing a disease for which a 5-HTi agonist is indicated, particularly a method of treating migraine or preventing migraine recurrence, in a mammal, including a human being, including simultaneous, separate or sequential administration by the oral route of (a) an effective amount of eletriptan, or a pharmaceutically acceptable salt thereof and (b) an effective amount of sodium bicarbonate.
7. The use of claim 5 or the method of claim 6 wherein (a) is eletriptan hydrobromide or eletriptan hemisulphate.
8. A pharmaceutical composition, adapted for oral administration, including a combination as defined in claim 1 or claim 2 and a pharmaceutically acceptable excipient.
9. A pharmaceutical composition as claimed in claim 8 in the form of a tablet.
10. A pharmaceutical composition as claimed in claim 9 comprising eletriptan hydrobromide, sodium bicarbonate, microcrystalline cellulose and magnesium stearate.
11 A product containing (a) eletriptan, or a pharmaceutically acceptable salt thereof and (b) sodium bicarbonate as a combined preparation for simultaneous, separate or sequential use, via oral administration, in the treatment or prevention of a disease for which a 5-HTi agonist is indicated, particularly in the treatment of migraine or in the prevention of migraine recurrence.
12. A product as claimed in claim 11 comprising the composition of any one of claims 8 to 10.
13. A product as claimed in claim 11 or claim 12 which further comprises a quantity of water suitable for facilitating oral administration of the eletriptan, or salt thereof, and sodium bicarbonate.
14. A product as claimed in claim 13 comprising either (a) two tablets, each containing 20mg of eletriptan (in the form of its hydrobromide salt) and about 630mg of sodium bicarbonate, and about 100ml of water or (b) one tablet containing 40mg of eletriptan (in the form of its hydrobromide salt) and about 630mg sodium bicarbonate and about 50ml of water.
5. A non-effervescent composition adapted for oral administration and gastrointestinal drug absorption comprising a 5- T^ agonist and sodium bicarbonate.
EP04724671A 2003-04-11 2004-03-31 Pharmaceutical combination comprising eletriptan and sodium bicarbonate Withdrawn EP1615635A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination
PCT/IB2004/001115 WO2004089365A1 (en) 2003-04-11 2004-03-31 Pharmaceutical combination comprising eletriptan and sodium bicarbonate

Publications (1)

Publication Number Publication Date
EP1615635A1 true EP1615635A1 (en) 2006-01-18

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04724671A Withdrawn EP1615635A1 (en) 2003-04-11 2004-03-31 Pharmaceutical combination comprising eletriptan and sodium bicarbonate

Country Status (12)

Country Link
EP (1) EP1615635A1 (en)
JP (1) JP2006522790A (en)
AR (1) AR044009A1 (en)
BR (1) BRPI0409127A (en)
CA (1) CA2521902A1 (en)
MX (1) MXPA05010070A (en)
NL (1) NL1025908C2 (en)
PA (1) PA8599901A1 (en)
PE (1) PE20050086A1 (en)
TW (1) TW200423929A (en)
UY (1) UY28260A1 (en)
WO (1) WO2004089365A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (en) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint SYNTHESIS OF 3 - {[(2R) -1-METHYLPYROLIDIN-2-IL] METHYL} -5- [2- (PHENILSULFONYL) ETYL] -1H-INDOL
JP6878021B2 (en) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 Pharmaceutical composition containing triptan and ascorbic acid
AU2019297360B2 (en) * 2018-07-03 2022-07-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (en) * 1986-08-01 1988-11-25 Zambon Spa PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (en) * 1993-03-26 1997-06-11 Zambon Spa PHARMECEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
CA2514875A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories International Srl Rapid absorption selective 5-ht agonist formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004089365A1 *

Also Published As

Publication number Publication date
TW200423929A (en) 2004-11-16
JP2006522790A (en) 2006-10-05
NL1025908C2 (en) 2005-11-22
AR044009A1 (en) 2005-08-24
BRPI0409127A (en) 2006-03-28
NL1025908A1 (en) 2004-10-13
UY28260A1 (en) 2004-11-30
WO2004089365A1 (en) 2004-10-21
CA2521902A1 (en) 2004-10-21
PA8599901A1 (en) 2005-02-04
PE20050086A1 (en) 2005-03-01
MXPA05010070A (en) 2005-11-23

Similar Documents

Publication Publication Date Title
JP5344620B2 (en) Solid formulation of olmesartan medoxomil and amlodipine
JP2006527195A (en) Composition comprising triptan and NSAID
US5468504A (en) Effervescent pharmaceutical compositions
JP3699969B2 (en) Pharmaceutical composition comprising a 5HT1 receptor agonist
AU2018347990A1 (en) Bi-layer pharmaceutical tablet formulation
PT812589E (en) "ANTIPIRETICAL AND ANALGESIC COMBINED PHARMACY"
US20040204475A1 (en) Pharmaceutical combination
AU2011339150B2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
CA2853117C (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
BG65309B1 (en) Use of eletriptan in the prevention of migraine recurrence
JPH05509293A (en) Use of 5-HT4 receptor antagonists in the treatment of arrhythmias and seizures
JP2002255814A (en) Pharmaceutical composition comprising aspirin
WO2004089365A1 (en) Pharmaceutical combination comprising eletriptan and sodium bicarbonate
JPH0678233B2 (en) Pharmaceutical preparation having antihypertensive and cardioprotective effects
JP2009535336A (en) Fixed combination dosage form for migraine treatment
KR100515311B1 (en) Dispersible Tablet Formulation Containing β-lactam Antibiotics and Process for Preparing the Same
US20220287973A1 (en) Orodispersible powder composition comprising a triptan
EP2246046A1 (en) Orally disintegrating olanzapine tablet
KR100188172B1 (en) Pharmaceutical compositions
TR2021020750A2 (en) COMBINATION OF DICLOPENAC AND ELETRIPTAN FOR ORAL DISTRIBUTION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20051111

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HUMPHREY, MICHAEL JOHN

Owner name: PFIZER LIMITED

17Q First examination report despatched

Effective date: 20080111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080903